Feasibility of BIBF1120 (nintedanib) combined with low-dose cytarabine in elderly patients with AML ineligible for intensive treatment.

被引：1
|
作者：
Krug, Utz [1 ]
Knoblauch, Nicola [1 ]
Gerss, Joachim [1 ]
Schliemann, Christoph [1 ]
Wiebe, Stefanie [1 ]
Mueller-Tidow, Carsten [1 ]
Berdel, Wolfgang E. [1 ]
机构：
[1] Univ Hosp Muenster, Munster, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.7053
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7053
引用
收藏
页数：1
相关论文
共 50 条
  • [11] TREATMENT OF DENOVO ACUTE MYELOGENOUS LEUKEMIA IN ELDERLY PATIENTS USING LOW-DOSE CYTARABINE
    TILLY, H
    CASTAIGNE, S
    SIGAUX, F
    DEGOS, L
    PRESSE MEDICALE, 1985, 14 (15): : 827 - 831
  • [12] EFFICACY OF LOW-DOSE CYTARABINE-BASED REGIMEN(CAG) FOLLOWED BY AZACITIDINE FOR ELDERLY PATIENTS WITH MDS/AML
    Tabayashi, Takayuki
    Takahashi, Yasuyuki
    Kimura, Yuta
    Tomikawa, Tatsuki
    Sagawa, Morihiko
    Anan, Tomoe
    Watanabe, Reiko
    Tokuhira, Michihide
    Mori, Shigehisa
    Kizaki, Masahiro
    ANNALS OF ONCOLOGY, 2014, 25
  • [13] Second-Line Low-Dose Cytarabine after First-Line Treatment with 5-Azacitidine in Elderly Patients with AML or High-Risk MDS Ineligible for Intensive Chemotherapy. A Retrospective Single Center Analysis
    Jakob, Christian
    Gunther, Benjamin
    Dittberner, Katharina
    Boger, Leonard
    Bleienheuft, Philipp
    Breywisch, Frank
    Rothmann, Frank
    Peinert, Stefan
    Maschmeyer, Georg
    BLOOD, 2015, 126 (23)
  • [14] Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML
    Visani, Giuseppe
    Loscocco, Federica
    Dennis, Mike
    Zuffa, Eliana
    Candoni, Anna
    Sensi, Alberto
    Giannini, Barbara
    Musuraca, Gerardo
    Mianulli, Anna Maria
    Clavio, Marino
    Rocchi, Marco
    Gibellini, Davide
    Navari, Mohsen
    Gilkes, Amanda
    Piccaluga, Pier Paolo
    Isidori, Alessandro
    BLOOD ADVANCES, 2020, 4 (20) : 5040 - 5049
  • [15] Comparative Effectiveness of Combination Glasdegib plus Low-Dose Cytarabine (GLAS plus LDAC) Vs Combination Venetoclax plus Low-Dose Cytarabine (VEN plus LDAC) Among Older Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (NIC): Indirect Treatment Comparison (ITC) Methods
    Westley, Tracy
    Forsythe, Anna
    Bell, Timothy J.
    Cappelleri, Joseph C.
    Chan, Geoffrey
    Tremblay, Gabriel
    BLOOD, 2018, 132
  • [16] Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis
    Qin, Yao
    Kuang, Pu
    Liu, Ting
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (02) : 219 - 227
  • [17] Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis
    Yao Qin
    Pu Kuang
    Ting Liu
    Clinical and Experimental Medicine, 2023, 23 : 219 - 227
  • [18] ORAL IDARUBICIN AND LOW-DOSE CYTARABINE AS THE INITIAL TREATMENT OF ACUTE MYELOID-LEUKEMIA IN ELDERLY PATIENTS
    HAROUSSEAU, JL
    HUGUET, F
    REIFFERS, J
    COLLOMBAT, P
    KOHSER, P
    LEPRISE, PY
    SOUTEYRAND, P
    HURTELOUP, P
    LEUKEMIA & LYMPHOMA, 1991, 5 (2-3) : 145 - 149
  • [19] Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan
    Asada, Noboru
    Ando, Jun
    Takada, Satoru
    Yoshida, Chikashi
    Usuki, Kensuke
    Shinagawa, Atsushi
    Ishizawa, Kenichi
    Miyamoto, Toshihiro
    Iida, Hiroatsu
    Dobashi, Nobuaki
    Okubo, Sumiko
    Honda, Hideyuki
    Soshin, Tomomi
    Nishimura, Yasuko
    Tsutsui, Atsuko
    Mukai, Harumi
    Yamamoto, Kazuhito
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (07) : 595 - 603
  • [20] MGA GUIDED INTENSIVE INDUCTION WITH HIGH DOSE CYTARABINE PLUS IDARUBICIN IN 149 AML ELDERLY PATIENTS
    Capelli, D.
    Saraceni, F.
    Chiarucci, M.
    Poloni, A.
    Discepoli, G.
    Leoni, P.
    Olivieri, A.
    HAEMATOLOGICA, 2015, 100 : 43 - 43
12345